MedPath

Orfagen

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:10
Completed:4

Trial Phases

3 Phases

Phase 1:2
Phase 2:2
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (33.3%)
Phase 2
2 (33.3%)
Phase 3
2 (33.3%)

Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis

Phase 3
Completed
Conditions
Uremic Xerosis
Interventions
Drug: V0034CR01B vehicle
First Posted Date
2010-03-10
Last Posted Date
2017-12-20
Lead Sponsor
Orfagen
Target Recruit Count
237
Registration Number
NCT01084148

Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis

Phase 3
Completed
Conditions
Uremic Xerosis
First Posted Date
2010-03-10
Last Posted Date
2010-03-10
Lead Sponsor
Orfagen
Target Recruit Count
100
Registration Number
NCT01084720

Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

Phase 2
Completed
Conditions
Idiopathic Solar Urticaria
Interventions
Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)
Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)
Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)
Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)
Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]
Drug: V0096 CR vehicle (formula RV3131A-MV1197)
First Posted Date
2007-06-07
Last Posted Date
2017-12-22
Lead Sponsor
Orfagen
Target Recruit Count
16
Registration Number
NCT00483496
Locations
🇺🇸

Henry Ford Medical Center, Detroit, Michigan, United States

🇺🇸

St Luke's Roosevelt Hospital Center, New York, New York, United States

🇬🇧

Ninewells Hospital, Dundee, United Kingdom

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

Phase 2
Completed
Conditions
Congenital Venous Malformation
Interventions
First Posted Date
2007-04-19
Last Posted Date
2015-01-15
Lead Sponsor
Orfagen
Target Recruit Count
32
Registration Number
NCT00462462
Locations
🇺🇸

Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

🇫🇷

Hôpital Bretonneau Service de neuroradiologie, Tours Cedex 1, France

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.